Cargando…

PARPs, PAR and NAD Metabolism and Their Inhibitors in Cancer

Detalles Bibliográficos
Autores principales:	Curtin, Nicola, Bai, Péter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7760776/ https://www.ncbi.nlm.nih.gov/pubmed/33255262 http://dx.doi.org/10.3390/cancers12123494

Ejemplares similares

The taming of PARP1 and its impact on NAD(+) metabolism
por: Hurtado-Bagès, Sarah, et al.
Publicado: (2020)

THU547 Role Of NAD(+) Synthesis Pathway In PARP Inhibitor Resistance
por: Myong, Subin, et al.
Publicado: (2023)

PARP inhibitors: the race is on
por: Brown, Jessica S, et al.
Publicado: (2016)

Differences in Durability of PARP Inhibition by Clinically Approved PARP Inhibitors: Implications for Combinations and Scheduling
por: Smith, Hannah L., et al.
Publicado: (2022)

Addicted to PAR?: A closer look at PARP inhibitor sensitivity
por: Altmeyer, Matthias
Publicado: (2012)

Bacteria boost host NAD metabolism
por: Shats, Igor, et al.
Publicado: (2020)

Discovery of an NAD(+) analogue with enhanced specificity for PARP1
por: Zhang, Xiao-Nan, et al.
Publicado: (2022)

NAD(+), Sirtuins and PARPs: enhancing oocyte developmental competence
por: POLLARD, Charley-Lea, et al.
Publicado: (2022)

Checkpoint and PARP inhibitors, for whom and when
por: Lee, Jung-Min, et al.
Publicado: (2017)

PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2?
por: Frizzell, Kristine M, et al.
Publicado: (2009)

Combining enzalutamide with PARP inhibitors: Pharmaceutically induced BRCAness
por: Thompson, Timothy C., et al.
Publicado: (2017)

PARP inhibitors as a radiosensitizer: a future promising approach in prostate cancer?
por: Angel, Martin, et al.
Publicado: (2021)

Repositioning PARP inhibitors for SARS‐CoV‐2 infection(COVID‐19); a new multi‐pronged therapy for acute respiratory distress syndrome?
por: Curtin, Nicola, et al.
Publicado: (2020)

Ozone Exposure Induces Metabolic Disorders and NAD+ Depletion Through PARP1 Activation in Spinal Cord Neurons
por: Ma, Shulin, et al.
Publicado: (2020)

NAD+ consumption by PARP1 in response to DNA damage triggers metabolic shift critical for damaged cell survival
por: Murata, Michael M., et al.
Publicado: (2019)

Interplay between compartmentalized NAD(+) synthesis and consumption: a focus on the PARP family
por: Cohen, Michael S.
Publicado: (2020)

NAD Metabolism in Cancer Therapeutics
por: Yaku, Keisuke, et al.
Publicado: (2018)

ATR Inhibition Potentiates PARP Inhibitor Cytotoxicity in High Risk Neuroblastoma Cell Lines by Multiple Mechanisms
por: Southgate, Harriet E. D., et al.
Publicado: (2020)

Decreased NAD+ in dopaminergic neurons
por: Sison, Samantha L., et al.
Publicado: (2018)

Extracellular NAD(+) enhances PARP-dependent DNA repair capacity independently of CD73 activity
por: Wilk, Anna, et al.
Publicado: (2020)

Coronavirus infection and PARP expression dysregulate the NAD Metabolome: an actionable component of innate immunity
por: Heer, Collin D., et al.
Publicado: (2020)

Coronavirus infection and PARP expression dysregulate the NAD metabolome: An actionable component of innate immunity
por: Heer, Collin D., et al.
Publicado: (2021)

Mitochondrial PARP1 regulates NAD(+)-dependent poly ADP-ribosylation of mitochondrial nucleoids
por: Lee, Jong-Hyuk, et al.
Publicado: (2022)

Flavonoid Apigenin Is an Inhibitor of the NAD(+)ase CD38: Implications for Cellular NAD(+) Metabolism, Protein Acetylation, and Treatment of Metabolic Syndrome
por: Escande, Carlos, et al.
Publicado: (2013)

PARP inhibitors in ovarian cancer
por: Cibula, David, et al.
Publicado: (2015)

PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia
por: Herriott, Ashleigh, et al.
Publicado: (2015)

Oncogene-induced NAD(+) depletion in tumorigenesis
por: Tummala, Krishna S., et al.
Publicado: (2015)

NAD(+) to assess health in aging humans
por: Janssens, Georges E., et al.
Publicado: (2022)

NAD+ Precursors: A Physiological Reboot?
por: Niño-Narvión, Julia, et al.
Publicado: (2023)

PARP inhibitors
por: Anwar, Maheen, et al.
Publicado: (2015)

The Enigmatic Function of PARP1: From PARylation Activity to PAR Readers
por: Kamaletdinova, Tatiana, et al.
Publicado: (2019)

NAD(+) deficit, protein acetylation and muscle aging
por: Ji, Li Li, et al.
Publicado: (2021)

Visualization of a DNA-PK/PARP1 complex
por: Spagnolo, Laura, et al.
Publicado: (2012)

PARP inhibitor combinations in prostate cancer
por: Pezaro, Carmel
Publicado: (2020)

PARP Inhibitors in Prostate and Urothelial Cancers
por: Garje, Rohan, et al.
Publicado: (2020)

PARP and PARG inhibitors in cancer treatment
por: Slade, Dea
Publicado: (2020)

Resistance to PARP-Inhibitors in Cancer Therapy
por: Montoni, Alicia, et al.
Publicado: (2013)

An update on PARP inhibitors for the treatment of cancer
por: Benafif, Sarah, et al.
Publicado: (2015)

PARP Inhibitors in Breast and Ovarian Cancer
por: Wang, Samuel S. Y., et al.
Publicado: (2023)

Advances in PARP Inhibitors for Prostate Cancer
por: Tisseverasinghe, Steven, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_a1jiht7p57m28j01a19ps210rc